KRAS and pancreatic neoplasm: To date, few studies have reported KRAS2 mutations in circulating DNA in patients with pancreatic cancer with a wide spectrum of sensitivity (27 to 81%) (Sorenson et al, 1994; Mulcahy et al, 1998; Yamada et al, 1998; Castells et al, 1999; Porta et al, 1999; Theodor et al, 2000).